B+
Bull case
20%
Probability
Target price
$27.18
Analysis reference price unavailable
Analysis 2026-02-14 · RankAlpha Sentiment AI
TXG
10x GenomicsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$18.54
Analysis reference price unavailable
Analysis 2026-02-14 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$12.68
Analysis reference price unavailable
Analysis 2026-02-14 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-02-14
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market sentiment is cautiously neutral: analyst medians cluster near the current price, implying limited consensus upside. Coverage shows wide dispersion (median ~$18.54, high outlier $57), reflecting polarized views on growth and adoption. Investors are focused on execution—consumables attach rates and margin inflection are the key swing factors.
RankAlpha Sentiment AI - 2026-02-14
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystNext quarterly earnings (estimated)High impact
Company quarterly results can drive near-term volatility; expectations and consensus targets are mixed in public sources [#SERP-3]. Using a conservative estimate for the next report window.[#SERP-3]
2026-12-31eventProduct launches / regulatory milestones (pipeline)High impact
Discrete product launches or regulatory/clearance milestones would be event-driven price movers; timing is uncertain so we assume a year-end window for planning.[#SERP-1]
2027-02-14catalystCommercial adoption of expanded multi-omics productsHigh impact
Broader market adoption of new product lines and multi-omics expansion could materially increase revenue over a multi-year horizon; consensus analyst notes emphasize platform opportunity [#SERP-4].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-14 • Updated nightlySource: Internal modelMethodology